Plain-English translation of NCT06801119 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage clinical trial testing a new medication called HN2301, which is given as an injection. The study is designed to see whether HN2301 is safe and whether it helps people with three specific autoimmune diseases: systemic lupus erythematosus (SLE), systemic sclerosis (also called scleroderma), and rheumatoid arthritis. Researchers will start with lower doses and gradually increase them to find the right balance between safety and effectiveness.
People with these autoimmune diseases often don't respond well enough to current treatments, and their conditions can cause serious damage to joints, skin, and organs. This trial is exploring whether this new medication might offer a better treatment option for patients who need additional help controlling their disease.
You likely qualify if…
You likely don't qualify if…
Participants will receive HN2301 injections at specified doses on certain study days. The study starts with lower doses and gradually increases them to test safety and find the right dose. You will be monitored closely with blood tests and other check-ups to see how your body responds and whether the medication helps your autoimmune disease symptoms improve.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Shenzhen MagicRNA Biotechnology Co., Ltd
Collaborators
The First Affiliated Hospital of University of Science and Technology of China
Enrollment target
~30 participants
Started
March 2025
Primary completion
December 2027
Age range
18 Years – 69 Years
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Zhu Chen, MD
The First Affiliated Hospital of University of Science and Technology of China
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.